News | April 16, 2025
Rising Pharma gets final approval from USFDA for Mesalamine Suppositories 1000 mg
The approved product, Mesalamine Suppositories 1000 mg, has an estimated U.S. market size of US$ 29 million
The approved product, Mesalamine Suppositories 1000 mg, has an estimated U.S. market size of US$ 29 million
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
More than 40 types of Amyloid proteins are discovered till date
The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date
Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis
Shilpa’s product has been approved as a generic version to the innovator - Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF Prism)
This partnership encompasses dossier licensing, bulk product supply, and the licensing of ZIM Labs’ proprietary Oral Thin Film technology platform, ThinOral
Introduces revolutionary approach to workflow management to enhance operational efficiency and optimize process efficiency
The Peptide Research Center is designed to support innovator pharma and biotech companies with specialized services across peptide synthesis, discovery, and advanced modalities, including complex conjugates
The stethoscope features high acoustic sensitivity and active noise cancellation, minimizing ambient interference to improve auscultation clarity, particularly in noisy hospital settings
Subscribe To Our Newsletter & Stay Updated
